Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, 6-Month Self-selection and Actual Use Study for Rx-to-OTC Switch of Rosuvastatin 5 mg Once-daily in Combination With a Web App

NCT04964544 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04964544
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04964544 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, 6-Month Self-selection and Actual Use Study for Rx-to-OTC Switch of Rosuvastatin 5 mg Once-daily in Combination With a Web App
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
July 8, 2021
Completion date
March 1, 2023
Enrollment
1,196 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high cholesterol